REGN logo

REGN Long term liabilities

Annual long term liabilities:

$4.46B+$777.80M(+21.11%)
December 31, 2024

Summary

  • As of today (May 24, 2025), REGN annual total long term liabilities is $4.46 billion, with the most recent change of +$777.80 million (+21.11%) on December 31, 2024.
  • During the last 3 years, REGN annual long term liabilities has risen by +$1.73 billion (+63.22%).
  • REGN annual long term liabilities is now at all-time high.

Performance

REGN Long term liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

quarterly long term liabilities:

$4.59B+$129.50M(+2.90%)
March 31, 2025

Summary

  • As of today (May 24, 2025), REGN quarterly total long term liabilities is $4.59 billion, with the most recent change of +$129.50 million (+2.90%) on March 31, 2025.
  • Over the past year, REGN quarterly long term liabilities has increased by +$793.40 million (+20.89%).
  • REGN quarterly long term liabilities is now at all-time high.

Performance

REGN quarterly long term liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

Long term liabilities Formula

Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities

REGN Long term liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+21.1%+20.9%
3 y3 years+63.2%+34.0%
5 y5 years+175.6%+192.6%

REGN Long term liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+63.2%at high+36.6%
5 y5-yearat high+175.6%at high+192.6%
alltimeall timeat high>+9999.0%at high>+9999.0%

REGN Long term liabilities History

DateAnnualQuarterly
Mar 2025
-
$4.59B(+2.9%)
Dec 2024
$4.46B(+21.1%)
$4.46B(+0.1%)
Sep 2024
-
$4.46B(+1.9%)
Jun 2024
-
$4.37B(+15.1%)
Mar 2024
-
$3.80B(+3.1%)
Dec 2023
$3.68B(+8.1%)
$3.68B(+0.6%)
Sep 2023
-
$3.66B(+3.5%)
Jun 2023
-
$3.54B(+2.0%)
Mar 2023
-
$3.46B(+1.6%)
Dec 2022
$3.41B(+24.7%)
$3.41B(+1.5%)
Sep 2022
-
$3.36B(-3.6%)
Jun 2022
-
$3.48B(+1.7%)
Mar 2022
-
$3.43B(+25.3%)
Dec 2021
$2.73B(-20.6%)
$2.73B(+1.3%)
Sep 2021
-
$2.70B(+2.8%)
Jun 2021
-
$2.63B(+1.9%)
Mar 2021
-
$2.58B(-25.1%)
Dec 2020
$3.44B(+112.5%)
$3.44B(-5.0%)
Sep 2020
-
$3.62B(+117.0%)
Jun 2020
-
$1.67B(+6.3%)
Mar 2020
-
$1.57B(-3.1%)
Dec 2019
$1.62B(+5.5%)
$1.62B(-3.0%)
Sep 2019
-
$1.67B(-2.1%)
Jun 2019
-
$1.70B(-10.2%)
Mar 2019
-
$1.90B(+23.7%)
Dec 2018
$1.53B(+3.3%)
$1.53B(+0.9%)
Sep 2018
-
$1.52B(+6.0%)
Jun 2018
-
$1.43B(-6.8%)
Mar 2018
-
$1.54B(+3.7%)
Dec 2017
$1.48B(+15.7%)
$1.48B(-1.7%)
Sep 2017
-
$1.51B(-2.9%)
Jun 2017
-
$1.56B(-5.3%)
Mar 2017
-
$1.64B(+28.1%)
Dec 2016
$1.28B(+12.2%)
$1.28B(-6.8%)
Sep 2016
-
$1.38B(+16.9%)
Jun 2016
-
$1.18B(-3.5%)
Mar 2016
-
$1.22B(+6.7%)
Dec 2015
$1.14B(+80.7%)
$1.14B(-0.7%)
Sep 2015
-
$1.15B(+96.1%)
Jun 2015
-
$586.97M(-15.1%)
Mar 2015
-
$691.01M(+9.2%)
Dec 2014
$632.76M(-9.6%)
$632.76M(-18.6%)
Sep 2014
-
$777.43M(+5.7%)
Jun 2014
-
$735.66M(-1.1%)
Mar 2014
-
$744.08M(+6.3%)
Dec 2013
$700.10M(+4.3%)
$700.10M(+2.7%)
Sep 2013
-
$681.52M(+0.1%)
Jun 2013
-
$681.12M(+1.3%)
Mar 2013
-
$672.41M(+0.1%)
Dec 2012
$671.55M(-2.6%)
$671.55M(-0.7%)
Sep 2012
-
$676.02M(-0.5%)
Jun 2012
-
$679.62M(-0.9%)
Mar 2012
-
$685.75M(-0.6%)
Dec 2011
$689.58M(+52.4%)
$689.58M(+63.6%)
Sep 2011
-
$421.54M(-2.6%)
Jun 2011
-
$432.96M(-2.5%)
Mar 2011
-
$443.95M(-1.9%)
Dec 2010
$452.56M(+80.4%)
$452.56M(-1.7%)
Sep 2010
-
$460.54M(+53.6%)
Jun 2010
-
$299.85M(+1.0%)
Mar 2010
-
$296.79M(+18.3%)
Dec 2009
$250.87M(+14.5%)
$250.87M(+22.0%)
Sep 2009
-
$205.58M(-2.8%)
Jun 2009
-
$211.41M(+25.9%)
Mar 2009
-
$167.99M(-23.3%)
Dec 2008
$219.03M
$219.03M(+28.0%)
Sep 2008
-
$171.19M(-2.9%)
Jun 2008
-
$176.31M(-4.3%)
DateAnnualQuarterly
Mar 2008
-
$184.32M(-4.2%)
Dec 2007
$192.33M(-40.5%)
$192.33M(-40.8%)
Sep 2007
-
$325.01M(+3.6%)
Jun 2007
-
$313.69M(-2.3%)
Mar 2007
-
$321.14M(-0.7%)
Dec 2006
$323.45M(+20.2%)
$323.45M(+24.4%)
Sep 2006
-
$260.01M(-1.2%)
Jun 2006
-
$263.06M(-1.1%)
Mar 2006
-
$266.10M(-1.1%)
Dec 2005
$269.14M(+5.0%)
$269.14M(+7.9%)
Sep 2005
-
$249.37M(-1.0%)
Jun 2005
-
$251.94M(-1.0%)
Mar 2005
-
$254.58M(-0.7%)
Dec 2004
$256.43M(-4.7%)
$256.43M(-0.6%)
Sep 2004
-
$257.91M(-1.1%)
Jun 2004
-
$260.67M(-1.9%)
Mar 2004
-
$265.74M(-1.2%)
Dec 2003
$268.99M(+30.9%)
$268.99M(-7.1%)
Sep 2003
-
$289.56M(+38.8%)
Jun 2003
-
$208.64M(+1.5%)
Mar 2003
-
$205.46M(-0.0%)
Dec 2002
$205.47M(-0.7%)
$205.47M(+0.2%)
Sep 2002
-
$205.15M(-0.3%)
Jun 2002
-
$205.81M(-0.3%)
Mar 2002
-
$206.44M(-0.3%)
Dec 2001
$207.02M(+1575.2%)
$207.02M(+2119.6%)
Sep 2001
-
$9.33M(-7.4%)
Jun 2001
-
$10.07M(-7.7%)
Mar 2001
-
$10.92M(-11.6%)
Dec 2000
$12.36M(-13.0%)
$12.36M(-2.0%)
Sep 2000
-
$12.61M(-3.9%)
Jun 2000
-
$13.12M(-6.2%)
Mar 2000
-
$13.99M(-1.5%)
Dec 1999
$14.20M(-12.9%)
$14.20M(-5.3%)
Sep 1999
-
$15.00M(-4.5%)
Jun 1999
-
$15.70M(-1.9%)
Mar 1999
-
$16.00M(-1.8%)
Dec 1998
$16.30M(-13.3%)
$16.30M(+2.5%)
Sep 1998
-
$15.90M(-15.4%)
Jun 1998
-
$18.80M(+1.6%)
Mar 1998
-
$18.50M(-1.6%)
Dec 1997
$18.80M(+0.5%)
$18.80M(+0.5%)
Sep 1997
-
$18.70M(-3.1%)
Jun 1997
-
$19.30M(+4.9%)
Mar 1997
-
$18.40M(-1.6%)
Dec 1996
$18.70M(+43.8%)
$18.70M(+6.9%)
Sep 1996
-
$17.50M(+3.6%)
Jun 1996
-
$16.90M(+24.3%)
Mar 1996
-
$13.60M(+4.6%)
Dec 1995
$13.00M(+41.3%)
$13.00M(+83.1%)
Sep 1995
-
$7.10M(-9.0%)
Jun 1995
-
$7.80M(-9.3%)
Mar 1995
-
$8.60M(-6.5%)
Dec 1994
$9.20M(+50.8%)
$9.20M(+13.6%)
Sep 1994
-
$8.10M(+9.5%)
Jun 1994
-
$7.40M(-10.8%)
Mar 1994
-
$8.30M(+36.1%)
Dec 1993
$6.10M(0.0%)
$6.10M(-4.7%)
Sep 1993
-
$6.40M(-3.0%)
Jun 1993
-
$6.60M(0.0%)
Mar 1993
-
$6.60M(+8.2%)
Dec 1992
$6.10M(+35.6%)
$6.10M(+8.9%)
Sep 1992
-
$5.60M(+7.7%)
Jun 1992
-
$5.20M(0.0%)
Mar 1992
-
$5.20M(+15.6%)
Dec 1991
$4.50M(-60.5%)
$4.50M(+28.6%)
Sep 1991
-
$3.50M(-10.3%)
Jun 1991
-
$3.90M(-65.8%)
Dec 1990
$11.40M
$11.40M

FAQ

  • What is Regeneron Pharmaceuticals annual total long term liabilities?
  • What is the all time high annual long term liabilities for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual long term liabilities year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?

What is Regeneron Pharmaceuticals annual total long term liabilities?

The current annual long term liabilities of REGN is $4.46B

What is the all time high annual long term liabilities for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual total long term liabilities is $4.46B

What is Regeneron Pharmaceuticals annual long term liabilities year-on-year change?

Over the past year, REGN annual total long term liabilities has changed by +$777.80M (+21.11%)

What is Regeneron Pharmaceuticals quarterly total long term liabilities?

The current quarterly long term liabilities of REGN is $4.59B

What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly total long term liabilities is $4.59B

What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?

Over the past year, REGN quarterly total long term liabilities has changed by +$793.40M (+20.89%)
On this page